The European Business Association (EBA) in September got 15 new members, including Ukrlandfarming, one of the largest agricultural holdings in terms of land bank, the UNIT.City innovative park, Biopharma pharmaceutical plant LLC and ADD (Apteka Dobroho Dnia) pharmacy chain.
According to the EBA, among its new members are also Aakon Grain Ukraine LLC with an elevator of 10,000 tonnes, providing agricultural machinery leasing services, Brovary Aluminum Plant from ALUMETA Group, and Art Nation of movie maker Eduard Akhramovych, working in the sphere of marketing.
Its new members also became Audit Consult Group LLC, the creators of premises for entrepreneurs Business Interiors LLC, a real estate company from Benish Group GmbH, Edwin Steel Corporation LLC and Goodgrainoil, selling grain and oilseeds.
According to the release, in addition, EBA members became Perenio, whose parent company Perenio IoT has its headquarters in the Czech Republic, Rent-a-car Ukraine LLC, an official representative of Europcar in Ukraine, and Skyrora UA, a subsidiary of British-based Skyrora Limited of Volodymyr Levykin.
The EBA told Interfax-Ukraine the total number of the association members reached 979 companies.
Kyiv-based producer of blood-derived products Biopharma is to boost exports by 60% in August 2018 year-over-year, to UAH 130 million. Exports in August will be 40% higher than the monthly average indicator during the year, the company’s press service said. In August 2018, the company will ship, in addition to Ukraine, to markets of 10 countries, including Belarus, Kazakhstan, India, Colombia, Uzbekistan, Azerbaijan, Middle East countries, as well as to Slovakia, Mongolia, and Bangladesh. It should be noted that Biopharma’s products will be delivered to Bangladesh and Colombia for the first time. The company’s plans include the expansion of its presence in the European markets.
Biopharma immunobiological pharmaceutical company is one of the ten largest Ukrainian producers of medicines. It produces more than 20 immunobiological preparations from donated blood, preparations obtained with the use of recombinant DNA technology and probiotics.
In 2015, the company invested $3.5 million in the reconstruction of Sumy region’s blood center, which currently accounts for 98.2% of donated blood in the region.
Biopharma plans to launch a plasma fractionation plant in 2018. The Biopharma Group of Companies includes LLC Biopharma Invest, LLC Biopharma Plasma Invest, LLC Biopharma Plasma, and LLC Fractionation Plant FZ Biopharma.
Biopharma, a blood products maker, plans to boost suppliers of its products to the traditional markets for the company and actively develop new ones – India, African countries, Biopharma Group President Kostiantyn Yefymenko has said in an interview with Interfax-Ukraine. The group plans to boost sales in Ukraine and supplies to Belarus, Kazakhstan, Uzbekistan, Azerbaijan, Armenia, Tajikistan, Kyrgyzstan and Georgia.
“At the same time, the most promising for us is the Indian market, and after it – Africa, where we will intensively increase our presence,” Yefymenko said.
Commenting on plans for expansion of activities in foreign pharmaceutical markets, he said that currently Biopharma “does not strongly focus on the EU countries” because of the conservatism of this market, although it delivers its drugs, in particular probiotics, to some European countries – Slovakia and the Czech Republic.
Biopharma is one of the ten largest Ukrainian producers of medicines. It produces more than 20 immunobiological preparations from donor blood, preparations obtained by recombinant DNA technology and probiotics.
Biopharma, a blood products maker, plans to bring tetanus immune globulin (TIG) to the market by the end of 2019, Biopharma Group President Kostiantyn Yefymenko has said in an interview with Interfax-Ukraine. “Taking into account the country’s needs, we are working on the specific tetanus immune globulin. We hope that we would be able to bring it to the market by late 2019,” he said.
Biopharma is one of the ten largest Ukrainian producers of medicines. It produces more than 20 immunobiological preparations from donor blood, preparations obtained by recombinant DNA technology and probiotics.
Biopharma, a blood products maker, intends by the end of 2018 to open two plasma centers in Kharkiv and one in Dnipro, it is also planned to build a center in Cherkasy, President of Biopharma Kostiantyn Yefymenko has told Interfax-Ukraine. “Now we are engaged in the construction of two plasma centers in Kharkiv. We have already rented premises with an area of 700 square meters and plan to rent another facility with an area of 1,500 square meters. We are also planning to build one more center in Dnipro, where we have already rented premises (733 sq m) and Cherkasy. In time, we will build in other regional centers,” he said.
Yefymenko said that at present conceptual projects, construction projects have been approved for plasma centers in Kharkiv and the Dnipro, permissions have been obtained and dismantling work commenced.
“We plan to launch our first center in Kharkiv in autumn, in Dnipro in December,” he noted.
Biopharma, which currently collects about 4 tonnes of blood plasma per month, expects that the opening of new plasma centers in the first quarter of 2019 will increase the amount of plasma collection to 20 tonnes a month. Biopharma is one of the ten largest Ukrainian producers of medicines. It produces more than 20 immunobiological preparations from donor blood, preparations obtained by recombinant DNA technology and probiotics.
Biopharma pharmaceutical company in 2017 won tenders under five medicine procurement programs funded by 2016 and 2017 national budgets held by international institutions, the company has told Interfax-Ukraine.
These are medicines to treat patients with primary immunodeficiency diseases, Anti-D Immunoglobulin to prevent ABO hemolytic disease of the newborn and medicines to treat patients with cancer and patients with disseminated sclerosis.
International institutions bought medicines under the cardio-vascular and cerebro-vascular disease programs using budget funds from the company.
Biopharma supplied around 48,000 packages of medicines via central procurement schemes.
Biopharma President Kostiantyn Yefymenko said, commenting on international procurement, that Biopharma’s request to review the results of a tender to procure blood factor held in 2017 using 2016 budget funds by the United Nations Development Program (UNDP), which Italy’s Kedrion won, was dismissed.
He said that it is impossible to challenge the results of these tenders, as international organizations procure using closed-door procedures and use immunity under the international law.
“I would say that we won a tender to supply thromboplastinogen using the 2017 local budget held by the Kyiv City Administration,” he said.
As reported, in May 2017, Biopharma announced that the company intended to seek a review of the decision on the results of a tender for the purchase of blood from the UNDP, the winner of which was recognized the Italian pharmaceutical company Kedrion, whose offer was 30% ($600,000) more expensive than that of the national manufacturer.
Commenting on the initiative to create the national procurement agency, Yefymenko expressed hope that a transparent system of own tenders to procure medicines that would create a system of incentives for national manufacturers would be created.
“Our pharmaceutical companies manufacture quite a wide range of products that are rather competitive in the global market and can cover most of our domestic market needs,” he said.
Biopharma is among the ten largest Ukrainian drug manufactures. Biopharma produces immunobiological preparations of blood, as well as drugs obtained by recombinant DNA technology and probiotics.
